Skip to main content
. 2017 Apr 18;8(24):39605–39617. doi: 10.18632/oncotarget.17174

Figure 2. Overexpression of Sphk2 contributes to cancer cell resistance to ATRA therapy.

Figure 2

(A) Soft agar colony assays showing the effect of increasing concentrations of ATRA on HCT-116 and HCT-116Sphk2 cell growth. (B) Efficacy of ATRA on HCT-116 and HCT-116Sphk2 tumor growth in xenografted nude mice. Mice were dosed with vehicle or ATRA at 20 and 30 mg/kg for three consecutive weeks. Tumor volume and body weight were measured every 3 days. Bars represent means ± S.D. of six mice. *, p < 0.05 vs. vehicle control.